KR20230018384A - T-형 칼슘 채널 조정제의 사용 방법 - Google Patents

T-형 칼슘 채널 조정제의 사용 방법 Download PDF

Info

Publication number
KR20230018384A
KR20230018384A KR1020227041859A KR20227041859A KR20230018384A KR 20230018384 A KR20230018384 A KR 20230018384A KR 1020227041859 A KR1020227041859 A KR 1020227041859A KR 20227041859 A KR20227041859 A KR 20227041859A KR 20230018384 A KR20230018384 A KR 20230018384A
Authority
KR
South Korea
Prior art keywords
dose
compound
subject
period
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227041859A
Other languages
English (en)
Korean (ko)
Inventor
키란 레디
가브리엘 벨포트
버나드 라비나
마리온 위트만
Original Assignee
프락시스 프리시젼 메디신즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프락시스 프리시젼 메디신즈, 인크. filed Critical 프락시스 프리시젼 메디신즈, 인크.
Publication of KR20230018384A publication Critical patent/KR20230018384A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Transmitters (AREA)
KR1020227041859A 2020-04-29 2021-04-28 T-형 칼슘 채널 조정제의 사용 방법 Pending KR20230018384A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063017140P 2020-04-29 2020-04-29
US63/017,140 2020-04-29
US202063050410P 2020-07-10 2020-07-10
US63/050,410 2020-07-10
US202063082946P 2020-09-24 2020-09-24
US63/082,946 2020-09-24
PCT/US2021/029539 WO2021222342A1 (en) 2020-04-29 2021-04-28 Methods of use of t-type calcium channel modulators

Publications (1)

Publication Number Publication Date
KR20230018384A true KR20230018384A (ko) 2023-02-07

Family

ID=78373913

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227041859A Pending KR20230018384A (ko) 2020-04-29 2021-04-28 T-형 칼슘 채널 조정제의 사용 방법

Country Status (11)

Country Link
US (1) US20230165847A1 (https=)
EP (1) EP4142764A4 (https=)
JP (1) JP2023524039A (https=)
KR (1) KR20230018384A (https=)
CN (1) CN115776894A (https=)
AU (1) AU2021263804A1 (https=)
BR (1) BR112022021946A2 (https=)
CA (1) CA3177277A1 (https=)
IL (1) IL297642A (https=)
MX (1) MX2022013595A (https=)
WO (1) WO2021222342A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114340670B (zh) 2019-07-11 2026-02-17 普拉克西斯精密药物股份有限公司 T-型钙通道调节剂的制剂及其使用方法
US20250170114A1 (en) * 2022-02-03 2025-05-29 Praxis Precision Medicines, Inc. Methods of treatment using t-type calcium channel modulators
AU2023244348A1 (en) * 2022-03-28 2024-10-10 Praxis Precision Medicines, Inc. Methods of using oligomeric compounds to treat scn2a-related disorders
EP4522271A4 (en) * 2022-05-09 2026-04-29 Praxis Prec Medicines Inc Methods of use of t-type calcium channel modulators
EP4673219A1 (en) * 2023-03-02 2026-01-07 Praxis Precision Medicines, Inc. Crystalline salt forms of n-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide and methods of use thereof
AU2024229946A1 (en) * 2023-03-02 2025-09-11 Praxis Precision Medicines, Inc. Crystalline salts of a t-type calcium channel modulator and methods of use thereof
WO2025188619A1 (en) * 2024-03-04 2025-09-12 Praxis Precision Medicines, Inc. Methods of treating parkinson's disease with t-type calcium channel modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377968B2 (en) * 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
JP6957460B2 (ja) * 2015-10-22 2021-11-02 カビオン・インコーポレイテッドＣａｖｉｏｎ， Ｉｎｃ． アンジェルマン症候群および関連する障害の処置方法
WO2017083867A1 (en) * 2015-11-12 2017-05-18 Afasci, Inc. Ion channel inhibitory compounds, pharmaceutical formulations and uses
CN110072521B (zh) * 2016-12-16 2022-11-29 爱杜西亚药品有限公司 包含t型钙通道阻断剂的药物组合
WO2018118101A1 (en) * 2016-12-21 2018-06-28 Praxis Precision Medicines, Inc. T-type calcium channel modulators and methods of use thereof
AU2018364659A1 (en) * 2017-11-10 2020-05-28 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating genetic epileptic disoders
IL300798B2 (en) * 2018-10-03 2025-09-01 Cavion Inc Treatment of skeletal tremor with (r)–2-(4–isopropylphenyl)–n-(1-(5-(2,2,2–trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
CN114340670B (zh) * 2019-07-11 2026-02-17 普拉克西斯精密药物股份有限公司 T-型钙通道调节剂的制剂及其使用方法
EP4522271A4 (en) * 2022-05-09 2026-04-29 Praxis Prec Medicines Inc Methods of use of t-type calcium channel modulators

Also Published As

Publication number Publication date
CA3177277A1 (en) 2021-11-04
IL297642A (en) 2022-12-01
MX2022013595A (es) 2023-01-24
WO2021222342A1 (en) 2021-11-04
EP4142764A4 (en) 2024-05-29
BR112022021946A2 (pt) 2023-01-17
CN115776894A (zh) 2023-03-10
EP4142764A1 (en) 2023-03-08
AU2021263804A1 (en) 2023-01-19
US20230165847A1 (en) 2023-06-01
JP2023524039A (ja) 2023-06-08

Similar Documents

Publication Publication Date Title
US12077502B2 (en) Formulations of T-type calcium channel modulators and methods of use thereof
KR20230018384A (ko) T-형 칼슘 채널 조정제의 사용 방법
CA2770698C (en) Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions
US20250295646A1 (en) Methods of use of t-type calcium channel modulators
US20250375380A1 (en) High strength single unit dose formulations and methods of use thereof
CN121943903A (zh) T-型钙通道调节剂的制剂及其使用方法
CN121943902A (zh) T-型钙通道调节剂的制剂及其使用方法
CN121943904A (zh) T-型钙通道调节剂的制剂及其使用方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20221129

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240424

Comment text: Request for Examination of Application